Patient-reported outcomes: what really matters to patients? - Authors' reply

Affiliations

¹ Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. Electronic address: d-cella@northwestern.edu.
² Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, MA, USA.
³ Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Comment

David Cella et al. Lancet Oncol. 2022 May.

. 2022 May;23(5):e199.

doi: 10.1016/S1470-2045(22)00216-9.

¹ Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA. Electronic address: d-cella@northwestern.edu.
² Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology, Boston, MA, USA.
³ Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Conflict of interest statement

The authors' declaration of interests remain the same as those disclosed in the original Article.

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
Cella D, Motzer RJ, Suarez C, Blum SI, Ejzykowicz F, Hamilton M, Wallace JF, Simsek B, Zhang J, Ivanescu C, Apolo AB, Choueiri TK. Cella D, et al. Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12. Lancet Oncol. 2022. PMID: 35032437 Free PMC article. Clinical Trial.
Patient-reported outcomes: what really matters to patients?
Hasanov E, Caceres JOH, Maskens DA, Giles RH, Schmitt AM. Hasanov E, et al. Lancet Oncol. 2022 May;23(5):e198. doi: 10.1016/S1470-2045(22)00156-5. Lancet Oncol. 2022. PMID: 35489342 No abstract available.